TY - JOUR
T1 - Evaluation of renal function in transplant patients on tacrolimus therapy
AU - Agarwala, Sangeeta
AU - Culligan, Emma
AU - Jain, Ashok
AU - McCauley, Jerry
AU - Shapiro, Ron
AU - Chakrabarti, Pradip
AU - Burckart, Gilbert
AU - Venkataramanan, Raman
PY - 2002
Y1 - 2002
N2 - Glomerular filtration rate (GFR), as measured by 24-hour creatinine clearance and clearance of iothalamate, and effective renal plasma flow (ERPF), as measured by the clearance of para-aminohippuric acid (PAH), were evaluated at 2 weeks, 1 month, and 3 months after transplantation in 8 renal transplant patients and at 1 month and 1 year after transplantation in 9 liver transplant patients receiving tacrolimus (Prograf®) therapy. In renal transplant patients, there was a significant increase in GFR after transplantation. There was no change in GFR at 1 and 3 months as compared to 2 weeks after transplantation, while ERPF (ml/min/1.73 m2) was lower (p < 0.05) at 3 months (212 ± 42) compared to 1 month (306 ± 118) after transplantation. In liver transplant patients, GFR and ERPF were below normal despite normal serum creatinine concentrations, but there was no difference in GFR or ERPF at 1 month and 1 year after transplantation. Although below normal, renal function was well preserved in transplant patients while receiving chronic tacrolimus therapy over the study period. Dosage alterations of renally eliminated drugs may be required for drugs with a narrow therapeutic index.
AB - Glomerular filtration rate (GFR), as measured by 24-hour creatinine clearance and clearance of iothalamate, and effective renal plasma flow (ERPF), as measured by the clearance of para-aminohippuric acid (PAH), were evaluated at 2 weeks, 1 month, and 3 months after transplantation in 8 renal transplant patients and at 1 month and 1 year after transplantation in 9 liver transplant patients receiving tacrolimus (Prograf®) therapy. In renal transplant patients, there was a significant increase in GFR after transplantation. There was no change in GFR at 1 and 3 months as compared to 2 weeks after transplantation, while ERPF (ml/min/1.73 m2) was lower (p < 0.05) at 3 months (212 ± 42) compared to 1 month (306 ± 118) after transplantation. In liver transplant patients, GFR and ERPF were below normal despite normal serum creatinine concentrations, but there was no difference in GFR or ERPF at 1 month and 1 year after transplantation. Although below normal, renal function was well preserved in transplant patients while receiving chronic tacrolimus therapy over the study period. Dosage alterations of renally eliminated drugs may be required for drugs with a narrow therapeutic index.
UR - http://www.scopus.com/inward/record.url?scp=0035998758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035998758&partnerID=8YFLogxK
U2 - 10.1177/009127002401102632
DO - 10.1177/009127002401102632
M3 - Article
C2 - 12092747
AN - SCOPUS:0035998758
SN - 0091-2700
VL - 42
SP - 798
EP - 805
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
IS - 7
ER -